Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)

Type: Poster Session

Time: Saturday June 1, 8:00 AM to 11:00 AM

Location: Hall A

Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)

Type: Poster Discussion Session

Time: Saturday June 1, 3:00 PM to 4:30 PM

Location: E450

Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2-negative breast cancer: Final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG)— COMET study.

Circulating Biomarkers

Developmental Therapeutics and Tumor Biology (Nonimmuno)

2019 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Discussion Session (Board #11)

J Clin Oncol 37, 2019 (suppl; abstr 3019)

Author(s): Jean-Yves Pierga, Amanda Silveira, Olivier Tredan, Marie-Laure Tanguy, Veronique Lorgis, Coraline Dubot, William Jacot, Anthony Goncalves, Marc Debled, Christelle Levy, Jean-Marc Ferrero, Christelle Jouannaud, Marie-Ange Mouret-Reynier, Florence Dalenc, Jerome Lemonnier, Frederique Berger, Charlotte Proudhon, Francois Clement Bidard; Institut Curie, Paris, France; Département d'Oncologie Médicale, Centre Léon Bérard, Lyon, France; Institute Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France; Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Department of Medical Oncology, Caen, France; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France; Department of Medical Oncology, Institut Claudius Regaud–IUCT Oncopole, Toulouse, France; Unicancer, Paris, France; Biostatistics Unit, INSERM U900, Institut Curie, Paris, France

Abstract Disclosures


Background: Circulating Tumor Cells (CTC) are independent markers of progression-free survival (PFS) and overall survival (OS) in patients (pts) with metastatic breast cancer (MBC). Monitoring circulating tumor DNA (ctDNA) can detect mutation associated with resistance to treatment and its variations reflect changes in tumor burden. We prospectively monitored CTC, Circulating Endothelial Cells (CEC), serum markers and ctDNA during first line chemotherapy for MBC. Methods: The French cohort COMET is a prospective study including first line HER2 negative pts receiving weekly paclitaxel and bevacizumab . Blood samples were obtained at baseline (BL) and before the second cycle of chemotherapy (C2).We present here the final planned analysis. Results: From 09/2012 to 11/2014, 286 patients were included: 198 for ctDNA, 251 for CEC and 283 for CTC. Median age was 56 years and 23% of pts had triple negative BC. At baseline, 71% of pts had ≥1 detectable CTC per 7.5 ml of blood (median 4 CTC, range 1- 30,000). With a threshold of ≥5 CTC, 49% of pts were positive at baseline and 22% at C2. For ctDNA, out of the first 196 pts analyzed, 147 had at least one somatic mutation (SNV) detected in plasma (75%). The average number of mutations per pt was 2.4 (range 1 to 9). Most commonly mutated genes were TP53 and GATA3. ESR1 was mutated in 10.6% of the pts and restricted to the ER+ subgroup. PIK3CA was mutated in 23.2% of the pts. Median Allelic Frequency was 9.1% . Only 68 pts (36%) had detectable ctDNA at C2. At baseline, CTC and ctDNA levels were correlated (r = 0.40, p < 0.0001). Despite no complete overlap, 24 pts (12%) had no CTC nor ctDNA detected at baseline. Median follow-up was 53 months and median OS was 32 months. Detectable CTC and ctDNA at baseline and at C2 were significantly associated with decreased PFS and OS. CEC and serum markers level had no prognostic value. At multivariate analysis, triple negative status, detectable ctDNA at C2, CTC ≥5 at C2 and grade 3 on primary tumor were independent prognostic factors. Conclusions: This is the largest prospective cohort assessing the respective prognostic values of early CTC and ctDNA changes in homogenously treated first line MBC pts. Early decrease of CTC and ctDNA after one cycle of chemotherapy are independent predictive markers of favorable outcome, with a stronger value for ctDNA compared to CTC. Clinical utility of early ctDNA variations monitoring and changes in mutation profile remain to be demonstrated. Clinical trial information: NCT01745757

Other Abstracts in this Sub-Category:


1. Genome-wide cell-free DNA fragmentation profiling for early cancer detection.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3018 First Author: Alessandro Leal
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - Circulating Biomarkers


2. Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3020 First Author: Ugo De Giorgi
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - Circulating Biomarkers


3. Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).

Meeting: 2019 ASCO Annual Meeting Abstract No: 3035 First Author: Brendan John Guercio
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - Circulating Biomarkers